Nuplazid Death

More than 200 deaths have been reported since Nuplazid was approved in April 2016 to treat hallucinations and delusions associated with Parkinson’s disease psychosis. The atypical antipsychotic medication has also been linked to more than 2,000 other adverse event reports, including life-threatening incidents, falls, insomnia, nausea, and fatigue.

Nuplazid Death Investigation

The nationwide law firm of Bernstein Liebhard LLP is investigating Nuplazid death reports and other adverse events potentially associated with this relatively new Parkinson’s disease medication. If you or someone you love died after being prescribed Nuplazid, please call (888) 994-5118 to get in touch with a qualified Nuplazid lawyer today.

Nuplazid Death Reports

Nuplazid was the first drug ever approved by the U.S. Food & Drug Administration (FDA) to treat Parkinson’s disease patents who suffer from hallucinations and delusions.

While Nuplazid is considered an atypical antipsychotic drug, it works differently than other medications in this class, in that it targets the brain’s serotonin receptors. These receptors are thought to play a role in delusions and hallucinations

Like all antipsychotic drugs, the Nuplazid label includes a Black Box Warning regarding an increased risk of death in elderly dementia patients.  However,  Acadia Pharmaceutical claims that it has fewer toxic side effects compared to other antipsychotics.

In November 2017, an analysis of the FDA’s adverse event database conducted by the Institute for Safe Medication Practices (ISMP) indicated that more than 244 deaths had been reported in connection with Nuplazid during the 12-month period ending in March 2017.

The FDA also received nearly 2,200 other adverse event reports involving Nuplazid, including cases of:

  • Hallucinations (487)
  • Confused state (258)
  • Complaints that the Nuplazid was ineffective (333)

“The overall message in these adverse event reports is that hundreds of health professionals are trying this new drug with their patients and reporting that either it is not providing the expected benefit or making some psychosis worse,” the ISMP report concluded. “The large number of deaths also remains a concern in a setting where increased mortality was at least suspected if not proven in the clinical trials.”

Nuplazid Clinical Trial Patients Had Double the Rate of Death Versus Placebo

Nuplazid won FDA approval based on a single six-week trial that involved just 200 patients.

Those who were prescribed Nuplazid had double the rate of deaths and adverse events compared to the placebo group. Earlier studies of the drug showed no benefits in treating hallucinations or delusions among Parkinson’s disease patients.

Though an FDA advisory committee voted 12-2 to recommend approval of Nuplazid, the lead on that panel indicated that he did not believe the drug’s benefits outweighed its risks.

Other panel members – including some who voted for approval – also expressed reservations, with one physician calling for larger studies once Nuplazid came on the market to better assess its safety and effectiveness.

Learn More about Filing a Nuplazid Wrongful Death Lawsuit

You may be entitled to compensation for medical bills, lost wages, pain and suffering, and more if you or someone you love died after being prescribed Nuplazid.

For a free, no-obligation review of your potential Nuplazid wrongful death lawsuit, please call (888) 994-5118.

  1. FDA (2016) “FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease”
  2. ISMP (2017) “QuarterWatch”
  3. CNN (2018) “FDA worried drug was risky; now reports of deaths spark concern”
Last Modified: April 11, 2018

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us on Google+ on Facebook on LinkedIn on Twitter on YouTube on Pinterest

Skip to content